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Abstract: Alefacept is the ﬁ  rst biological agent approved by the US Food and Drug Admin-
istration (FDA) for the treatment of moderate to severe chronic plaque psoriasis. It is a full 
human fusion protein binding to CD2 on T cells. With its dual mechanism of action, alefacept 
blocks the interaction between the leukocyte-function-associated antigen (LFA)-3 and CD2 
and thereby impedes the activation and proliferation of T cells. In addition, alefacept induces 
apoptosis of activated memory T cells. This paper presents an overview about the clinical 
studies on alefacept, its mechanism of action, and the results of the clinical trials focused on 
efﬁ  cacy and safety of alefacept in different populations. Further on, data available on the use 
of alefacept in combination with other therapeutic agents are discussed.
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Introduction
Psoriasis is a chronic, inﬂ  ammatory skin disorder, which affects up to 2% of the popula-
tion worldwide (Christophers 2001). It has been shown that genetic and environmental 
factors inﬂ  uence the severity of the disease (Elder et al 2001; Lebwohl 2003). The 
most common type, chronic plaque psoriasis, shows well demarked plaques covered 
by silver scales which are often located symmetrically and bilaterally. The extensor 
surfaces (elbows and knees), the lower back, scalp, and the nails are involved most 
often. In severe cases the plaques can affect the whole body. Approximately 30% of 
the patients suffer from psoriatic arthritis, which is an inﬂ  ammatory, sero-negative 
arthritis with variable course (Korman and Moul 2005). Mild forms of psoriasis can 
be controled by topical treatment (such as topical steroids, vitamin D derivates, selec-
tive retinoids, anthralins), whereas the therapy of moderate to severe forms consists of 
phototherapy (ultraviolet B light or psoralen plus ultraviolet A light) combined with a 
variety of systemic treatment forms, such as methotrexate, oral retinoids, cyclosporine, 
6-azathioprine, and fumaric acid. However, all of these therapeutic options are limited: 
topical treatment is unsuitable to treat larger areas; chronic steroid use has common 
side-effects, such as skin atrophy, striae, and teleangiectasiae. Phototherapy can lead 
to photo-aging of the skin and to an increased risk of skin cancer (Korman and Moul 
2005). Besides that, long-term use of the systemic agents is limited by serious side-
effects including myelosuppression, hepatotoxicity, impairment of the renal function 
and teratogenicity (Luba and Stulberg 2006).
Psoriasis is regarded as a Th1 pre-dominated inﬂ  ammatory autoimmune disease. 
It is supposed that after contact with an unknown antigen, a subset of T cells develops 
into memory CD4+ and CD8+ T cells. These cells proliferate and migrate from the Therapeutics and Clinical Risk Management 2007:3(3) 412
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lymph nodes to the skin where they initiate a cutaneous in-
ﬂ  ammatory reaction and the production of pro-inﬂ  ammatory 
mediators (Krueger 2002). 
Alefacept: mechanisms of action
Alefacept (Amevive®, Astellas Pharma US, Inc.) is a 
full dimeric human fusion protein, which consists of an 
extracellular portion of the human leukocyte function anti-
gen-3 (LFA-3) fused to the Fc portion of immunoglobulin 
G1 (Figure 1).
Two main signals are required to initiate the activation, pro-
liferation, and cytokine secretion of  T cells (Robert and Kupper 
1999): (1) The presentation of an antigen in association with 
the major histocompatibility class complex (MHC) of antigen 
presenting cells (APC) to the T cell receptor (TCR) combined 
with (2) the activation of T cells via costimulatory signals by 
APC which can be mediated by bridging of the lymphocyte 
function antigen (LFA)-3 on APC and CD2 on T cells.
Alefacept binds competitively to the CD2 on the surface 
of T cells with the LFA-3 portion of the drug and efﬁ  ciently 
interferes with LFA-3/CD2 binding and thereby T cell activa-
tion (Miller et al 1993), whereas the Fc portion of alefacept 
engages the immunoglobulin receptor FcγRIII on the surface 
of natural killer cells resulting in apoptosis of speciﬁ  c memory 
T cell subsets (Majeau et al 1994). Since the CD2 expression 
is higher on memory than on naïve T cells (Sanders et al 
1988), alefacept binds mainly to memory T cells and induces 
a selective reduction of speciﬁ  c T cell subtypes by apoptosis. 
This means that alefacept can inhibit T cell activation on the 
one hand and selectively deplete memory T cells on the other 
hand (Langley et al 2005).
Pharmacokinetics and 
pharmacodynamics of alefacept
Alefacept is detectable 6 hours after intramuscular injection 
in the sera of the patients and the concentration peaks after 
a time period of 24–192 hours. Once absorption is complete, 
the elimination has a half-life of approximately 12 days 
(Vaishnaw and TenHoor 2002) and the excretion follows a 
ﬁ  rst order elimination (Liu et al 2004). The effect of renal 
or hepatic impairment on the pharmacokinetic of alefacept 
has not been evaluated in detail yet.
Following its mechanism of action alefacept reduces cir-
culating memory T cells (CD4+CD45RO+ and CD8+CD45RO+) 
thereby decreasing the count of total lymphocytes, 
whereas the number of naïve T cells (CD4+CD45RA+ and 
CD8+CD45RA+) remains approximately normal. Addition-
ally, alefacept does not have any functional effect on CD19+ B 
cells or CD16+/CD56+ natural killer (NK) cells (Gordon et al 
2003; Ortonne et al 2003). The selective effect of alefacept 
on memory T cells is of particular immunologic importance, 
since it has been shown previously that the reduction of 
pathogenic memory T cells goes along with the improvement 
of psoriasis (Ellis and Krueger 2001; Ortonne et al 2003). 
Figure 1 Overview of the structure of the human fusion protein alefacept. 
Abbreviations: IgG, immunoglobulin G; LFA, leukocyte function antigen.Therapeutics and Clinical Risk Management 2007:3(3) 413
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Most importantly, in patients receiving multiple doses of 
alefacept no cumulative effect mirrored by further reduction 
of the total number of lymphocytes or the number of T cell 
subsets has been observed (Gordon et al 2003; Ortonne et al 
2003; Lowe et al 2003).
Dosage and administration 
of alefacept
Alefacept administration was studied as a weekly intrave-
nous (i.v.) 7.5 mg administration as well as intramuscular 
(i.m.) 15 mg injection. In different studies both formulations 
showed similar safety and efﬁ  cacy proﬁ  les (Vaishnaw and 
TenHoor 2002).
The currently recommended dose is 7.5 mg given once 
a week as an i.v. bolus or 15 mg administered i.m. once a 
week for 12 weeks and an interval of 12 weeks without treat-
ment between courses. Although an i.m. application is more 
convenient for drug administration, the drug injection side 
reactions occur more often after i.m. than after i.v. applica-
tion. Since both ways of administration require application 
by a health care professional, patients have to visit the doctor 
weekly. In particular for patients with low compliance these 
weekly visits ensure continuous drug applications and the 
control of the respective clinical response.
Recently an open-labeled study, which evaluated the 
bioequivalence of subcutaneous (s.c.) application com-
pared with i.m. administration of alefacept (Sweetser et al 
2006), showed very similar pharmacodynamic effects 
for both ways of application. Even the total number of 
lymphocytes and lymphocyte subsets was similar for 
both routes of administration, so that s.c. application of 
alefacept might offer a convenient alternative way of 
administration especially for compliant patients who are 
unable to organize weekly ofﬁ  ce visits and who want to 
self-administer the drug at home.
Efﬁ  cacy of alefacept
In most of the studies the clinical efﬁ  cacy of alefacept was 
evaluated with the help of the Psoriasis Area Severity Index 
(PASI), a score ranging from 0 (no psoriasis) to 72 (the most 
severe form of the disease possible) combining scores for the 
degree of erythema, induration, desquamation, and the body 
surface area affected (Liu et al 2004). 
Different phase II and III clinical trials evaluated the 
efﬁ  cacy of a single as well as of multiple courses of alefacept. 
In an early placebo-controlled, double-blind multi-center 
phase II study completed in 2001, 229 patients receiving a 
30-second i.v. bolus alefacept at varying weight-adjusted 
doses (0.025, 0.075, and 0.150 mg/kg body weight) or placebo 
weekly for 12 weeks with a 12-week follow-up period have 
been examined (Ellis and Krueger 2001). According to the 
results of this study, a dosage of 0.075 mg alefacept was 
most effective. In 63% of the patients treated with 0.075 
mg alefacept a >50% reduction of the PASI (PASI 50) was 
achieved and in about 31% of patients a 75% reduction of 
the PASI (PASI 75) was reached 12 weeks after treatment 
(Figure 2A and 2B) (Ellis and Krueger 2001). In comparison 
with other studies, it has to be remembered that in this study 
Figure 2 Schematic summary of studies on the reduction of the psoriasis area severity index (PASI) induced by alefacept treatment (from data of Ellis CN, Krueger GG. 
2001) (A) PASI ≥75 and (B) PASI ≥50.Therapeutics and Clinical Risk Management 2007:3(3) 414
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the PASI achievements were based on cumulative success 
rates. Using the evaluation criterion of other studies, which 
means PASI 75 achieved at week 14, about 21% of patients 
achieved PASI 75 at week 14.
The ﬁ  rst phase III study completed in 2002 evaluated the 
efﬁ  cacy of 2 courses of alefacept (Krueger et al 2002). 553 
patients with chronic plaque psoriasis received two courses 
with i.v. application of a non-weight-adjusted dose of 7.5 mg 
alefacept or placebo once a week for 12 weeks each, followed 
by a 12-week phase without treatment. In this study a PASI 
75 was achieved in 28% of the patients and a PASI 50 in 
56% of the alefacept-treated patients during treatment and 
follow-up control after the ﬁ  rst course. In patients receiving 
a second course, the efﬁ  cacy increased signiﬁ  cantly: in 40% 
of those patients a 75% reduction was achieved and in 71% 
of the patients a 50% or greater reduction of the PASI was 
reached (Figure 3A). In both courses the decrease of the PASI 
peaked 8 weeks after the treatment course. 
Concerning the efﬁ  cacy of i.m. application of alefacept, 
an international, randomized, double-blind, placebo-
controlled phase III study was completed in 2003 (Lebwohl 
et al 2003). In this study 507 patients were randomized to 
receive 2 different doses of alefacept (10 mg or 15 mg) or 
placebo administered i.m. once a week for a total of 12 
weeks with a 12 week follow-up period. An overall PASI 50 
response was achieved in 57% patients treated with alefacept 
15 mg i.m., and a >50% reduction in PASI was achieved in 
53% of patients treated with 10 mg i.m. in comparison with 
a 35% reduction of PASI in the placebo group. At least a 
75% reduction in PASI throughout the study period has 
been achieved in 33% of patients treated with 15 mg i.m., 
in 28% of patients treated with 10 mg alefacept i.m., and in 
8% of the placebo group (Figure 3B). Data are consistent 
with the results from earlier studies mentioned above, in 
which alefacept was administered by an i.v. bolus (Ellis 
and Krueger 2001; Krueger et al 2002); therefore, the i.m. 
application of alefacept represents a convenient alternative 
route of administration. An overview of the results of studies 
on alefacept is provided in Table 1. 
Safety and tolerability of alefacept
During all studies the incidence of (opportunistic) infec-
tions and malignancies was monitored. The patients were 
also tested for development of speciﬁ  c antibodies against 
alefacept. In different phase II and III clinical trials the 
safety and tolerability of alefacept has been reported in 
detail (Krueger et al 2002; Lebwohl et al 2003; Lowe et al 
2003). The incidence of serious adverse events, discon-
tinuations, infections, malignancies, and the development 
of anti-alefacept antibodies was low. No correlation was 
noted between the overall incidence of infections and 
decreased CD4+ T cell counts and no cases of signiﬁ  cant 
sustained T cell suppression have been observed. Further, 
no opportunistic infections such as reactivation of herpes 
simplex virus have been observed (Lebwohl et al 2003). 
Most malignancies observed were cutaneous carcinomas 
such as basal cell and squamous cell carcinomas. The rate of 
malignancy was not greater than in the average population 
(Wong and Lebwohl 2003). The only side-effects observed 
in greater frequency in the group treated with alefacept were 
Figure 3 Schematic summary of the study data on different courses of Alefacept treatment (from data of Krueger et al 2002) (A), and results achieved with intramuscular 
application of different doses of alefacept versus placebo (from data of Lebwohl et al 2003) (B).Therapeutics and Clinical Risk Management 2007:3(3) 415
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common colds occurring soon after treatment but limited 
to the early treatment phase (Krueger et al 2002). In spite 
of the fact that alefacept leads to a reduction in T cell sub-
sets, the comparable T cell responses of patients treated 
with alefacept and healthy individuals could be explained 
mainly by the fact that alefacept targets only pathogenic 
T cells (Gottlieb et al 2003).
In 2002 a safety report based on data of 1359 patients 
who have received i.v. or i.m. alefacept in placebo – con-
trolled trials was published. The most common adverse 
events reported were headache, nasopharyngitis, upper 
respiratory tract infections, pruritus, ﬂ  u-like symptoms, 
dizziness, and nausea, whereas the rate of adverse events 
was similar in alefacept treated patients and controls. In 
ﬁ  ve patients, malignancies occurred concomitantly to treat-
ment but turned out to be independent from the study drug. 
Additionally, no correlation has been observed between 
the overall incidence of infections and decreased CD4+ 
T cell counts.
Concerning the injection site reactions, only one case 
led to a discontinuation of the alefacept therapy. In a 
clinical trial in which alefacept was administered i.m., 
16% of the patients treated with alefacept compared with 
8% of the patients who received a placebo developed 
injection site reactions such as pain, inflammation, 
bleeding, oedema, unspecific reactions, or very rarely 
hypersensitivity (Scheinfeld 2005a).
To evaluate the effect of alefacept treatment on T cell 
mediated immune responses, primary and secondary immune 
responses to a harmless T cell-dependent neo-antigen 
(øX174, a bacteriophage, ie, a virus that infects bacteria) 
and acquired immune response to a recall antigen (tetanus 
toxoid) under alefacept-treatment have been evaluated in a 
prospective, multicenter, randomized parallel-group phase 
II clinical study published in 2003 (Gottlieb et al 2003). In 
this study it has been shown that a 12-week course of ale-
facept treatment had no effect on the primary or secondary 
antibody response in vitro. The in vitro response to both 
the neoantigen and the known antigen of T cells of patients 
treated with alefacept was comparable to the response of 
T cells of the control group. 
Long-term efﬁ  cacy and safety 
of alefacept
Concerning the remission times, a study accomplished in 
2003 showed that a PASI 50 has been maintained for a me-
dian period of 7 months in a subgroup of 54 patients treated 
with alefacept (Lebwohl et al 2003; Papp 2006). In another 
group of patients, a reduction of the PASI greater or equal 
to 50% was reached and maintained for a period of over 4 
months. 
Repeated treatment courses are often necessary in order 
to control the chronic relapsing course of psoriasis. Patients 
treated with more than one 12-week course showed a longer 
duration of response compared with those treated with a sin-
gle course only. In different phase III studies, the safety and 
efﬁ  cacy of up to two courses of alefacept has been evaluated. 
Data presented in 2005 at the 63rd Annual Meeting of the 
American Academy of Dermatology showed an increase of 
the PASI 75 response rates for alefacept given i.v. from 29% 
during the ﬁ  rst course of therapy (n = 521) to 54% during the 
ﬁ  fth course (n = 39). PASI 50 was achieved in 56% of patients 
during the ﬁ  rst course and was enhanced to a maximum of 
74% of patients during the ﬁ  fth course (Menter et al 2006). 
However, because of the fact that the number of patients 
involved decreased from 521 to 39 it cannot be excluded that 
only responders have been positively selected in this study 
and non-responders dropped out, which would profoundly 
inﬂ  uence the efﬁ  cacy of the treatment. This should be kept in 
mind when evaluating the overall efﬁ  cacy of such a therapy 
for the average cohort of psoriasis patients.
The result of long-term use of the i.m. formulation was 
evaluated using the physician global assessment scale (PGA), 
a seven point scale, which the physician uses to assess the 
severity of the psoriasis plaques. 21% of the patients (n = 457) 
have been classiﬁ  ed using PGA as cleared or almost cleared 
after one course of alefacept given i.m. The PGA response 
increased to 41% during course 4 (n = 100). However, dur-
ing course 5 the response rate decreased to less than 30% 
(n = 50). Therefore, further studies need to evaluate if there 
is a possible limitation to the improvement of the disease 
after several courses of alefacept treatment and if it would 
be helpful to select only responders for the treatment, and, if 
so, which read-out parameters for the selection of responders 
and differentiation from non-responders would be the best in 
order to save time and costs by not treating non-responders 
for a long time.
In 2005, an integrated analysis of data from 13 clinical 
trials with 1869 patients affected by chronic plaque psoriasis 
who had received up to 9 courses of alefacept over a 5-year 
period was published. In this study the safety and tolerability 
of alefacept for long-term treatment was assessed (Goffe et al 
2005). Consistent with early reports, the most common infec-
tious side-effects, which remained similar between courses, 
were headache (14%) nasopharyngitis (10%), inﬂ  uenza (8%), 
upper respiratory tract infections (8%), and pruritus (8%). Therapeutics and Clinical Risk Management 2007:3(3) 417
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The infections were mild to moderate and resolved with 
conventional treatment. 
Consistent with its composition as a full human fusion 
protein, alefacept has a low immunogenicity although the 
development of antibodies against alefacept is possible. 
Less than 1% of the patients developed a low antibody titer 
(<1:40), but consistent with previous studies (Lebwohl 
et al 2003) anti-alefacept antibodies were not associated 
with hypersensitivity, did not amplify the treatment course, 
and most probably did not neutralize the efﬁ  cacy of the 
drug. Additionally, no increase in the number of patients 
developing antibodies against alefacept occurred during the 
treatment with alefacept over multiple courses. The data 
show that the incidence of adverse effects and discontinua-
tions because of adverse effects, infections, and malignancies 
does not increase in patients treated with multiple courses 
in comparison with patients with one course. Additionally, 
no evidence for a rebound phenomenon or worsening of 
psoriasis with discontinuation of alefacept has been reported. 
Despite these positive results there are no sufﬁ  cient data to 
exclude a potential negative inﬂ  uence of a long-term use 
of alefacept. Therefore, further studies and observations on 
the long-term safety and efﬁ  cacy of alefacept therapy are 
indispensable (Papp 2006).
Safety and efﬁ  cacy of alefacept 
in speciﬁ  c risk-groups
Recently the safety and efﬁ  cacy of alefacept in patient groups at 
higher risk for adverse events (old, obese, and diabetic patients) 
was evaluated (Gottlieb et al 2005). Based on the data of these 
studies, the safety proﬁ  le of alefacept administered to speciﬁ  c 
risk-groups did not differ from the safety proﬁ  le of the general 
population. Even multiple courses of alefacept did not lead to 
increased adverse effects in high-risk patients. However, due 
to the limited sample sizes additional data are required in order 
to conﬁ  rm these results. With regard to the increasing incidence 
of infections and malignancies with increasing age, careful 
evaluation of the patients’ history and associated diseases is 
recommended, particularly in older patients.
In 2005 a report of two patients who received alefacept 
while testing positive for hepatitis C virus (HCV) was pub-
lished (Thaci et al 2005). Because of its mechanism of action, 
alefacept led to transient decreases in CD4+ and CD8+ T cell 
counts in these patients. However, these reductions did not 
increase the HCV viral load or exacerbate the HCV infec-
tion. In both cases liver enzymes remained stable throughout 
the treatment and follow-up periods. The use of alefacept in 
patients suffering from an active or reactive chronic viral 
infection has to be evaluated carefully in future, considering 
the risk of reactivation or aggravation of the existing infection 
by an immunosuppressive agent like alefacept.
A small number of women included in clinical trials 
became pregnant while being treated with alefacept. Al-
though there have been no reports of any birth defects caused 
by alefacept, the effects on the fetal immune system and the 
post-natal immune functions in humans are still unknown. 
Safety and efﬁ  cacy of alefacept 
combination therapy
The safety and efﬁ  cacy of alefacept in combination with 
various therapies including topical steroids, methotrex-
ate, cyclosporine, narrowband and broadband ultraviolet 
B light (UVB), systemic retinoids, vitamin D derivatives, 
and prednisone is currently being evaluated in an ongoing 
international study, in which approximately 400 patients 
with chronic plaque psoriasis receive multiple courses of 
alefacept administered i.m. in combination with different 
other therapies (Gordon et al 2005). In general, patients who 
are candidates for alefacept combination therapy should have 
required systemic therapy before because of the severity of 
their disease which is not responsive to topical therapy and 
should have normal circulating CD4+ counts. Preliminary 
data available on effectiveness of alefacept in combination 
with topical therapies, UVB, oral retinoids, methotrexate, or 
cyclosporin did not show any increase of the adverse events 
compared with alefacept monotherapy (Gordon et al 2005). 
The incidence of serious infections remained low (0.7%), and 
no opportunistic infections and no increased liver toxicity 
from methotrexate or renal toxicity from cyclosporine has 
been observed (Gordon et al 2005).
A combination of etanercept, a recombinant tumor-
necrosis factor (TNF)-α fusion protein, and alefacept was 
evaluated in three patients who did not show sufﬁ  cient clini-
cal improvement under etanercept monotherapy. After the 
addition of alefacept the clinical response increased (Krell 
2006), indicating that even the combination of different 
biologicals with synergistic modes of action might be suc-
cessful in single cases.
Side-effects and contraindications 
of alefacept
Because of the important role T cells play as defender cells of 
the immune system, a selective reduction of speciﬁ  c T cell sub-
sets by alefacept might predispose patients receiving alefacept Therapeutics and Clinical Risk Management 2007:3(3) 418
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to various infections and to the development of malignancies. 
Although no evidence for an increased risk of malignancies 
has been reported, it will take long-term follow-up studies 
to ﬁ  nally determine whether or not the risk of malignancies 
increases after long-term treatment with alefacept. Alefacept is 
contraindicated in all patients with a history of systemic malig-
nancies such as lymphoma or leukemia. If a patient develops a 
malignancy under alefacept treatment the administration of the 
drug should be discontinued. Due to the fact that treatment with 
alefacept results in a selective reduction of memory T cells, 
monitoring of  T cell counts is recommended. The US product 
labeling recommends monitoring of CD4+ T cell counts every 
2 weeks during the 12-week treatment course. At the onset of 
the alefacept treatment the CD4+ lymphocyte counts should 
be at least ≥400 cells/µL. If these counts decrease below 250 
cell/µL the dose should be reduced and monitoring every week 
instituted. If the counts remain below this level for a month, 
alefacept should be discontinued (Biogen Idec Inc. 2005). 
Alefacept should not be administered to patients infected 
with human immunodeﬁ  ciency virus (HIV) because of a pos-
sible disease acceleration and complication after a signiﬁ  cant 
reduction of CD4+ T cells. Further, the use of alefacept is con-
traindicated if there is a known hypersensitivity to alefacept. 
In breast-feeding mothers application is not recommended 
because of the potential excretion of the drug into human 
milk (Biogen Idec Inc. 2005). 
Alefacept in psoriatic arthritis
In 2002 a prospective, open-labeled pilot study was performed 
to evaluate the clinical effect and changes in the synovium of 
patients suffering from active psoriatic arthritis (PsA) receiv-
ing treatment with alefacept (Kraan et al 2002). A dosage of 
7.5 mg alefacept was administered i.v. in weekly intervals 
during a total time period of 12 weeks. At baseline as well 
as after 4 and 12 weeks clinical evaluations were conducted, 
which included an examination of the joints for swelling and 
tenderness, morning stiffness, and pain which was classiﬁ  ed 
by a visual analogue scale. At the same time arthroscopic 
synovial biopsies were taken. They showed an improvement 
in the clinical picture as well as changes of the inﬂ  ammation 
in synovial tissue after treatment with alefacept. 
Alefacept in palmoplantar pustular 
psoriasis (PPP)
Palmoplantar pustular psoriasis (PPP) is a form of psoriasis 
characterized by recurrent crops of sterile pustules on the 
palms and soles, which erupt repeatedly over months or 
years. Many different treatments have been used for PPP 
but none has been generally accepted as being reliably 
effective. Recently a case of successful treatment of a 
patient suffering from a severe form of PPP with alefacept 
has been reported (Yeung-Yue et al 2005). After treatment 
with a total of 17 doses of alefacept the lesions on his palms 
and soles improved: erythema as well as the number of 
pustules was clearly regressive. Twelve weeks after the 
last alefacept treatment nearly all lesions were cleared. The 
clinical improvement remained for a minimum of 19 weeks 
after the last application of alefacept. An additional report 
described the successful use of alefacept in 2 patients with 
extensive and recalcitrant palmoplantar psoriasis (Myers 
et al 2005). In one of the two patients, clinical improvement 
could be observed after just 5 doses of alefacept. After the 
completion of the ﬁ  rst course (12 doses of 15 mg alefacept 
weekly) this patient showed further improvement. The 
second patient improved after the ﬁ  rst course of therapy, 
too. However, 5 weeks after the last application, diffuse ery-
thema of the pales and soles with moderate scaling occurred 
and substantial improvement could be achieved only after 
a second course of alefacept treatment. In order to conﬁ  rm 
these data of alefacept as a useful treatment alternative for 
patients suffering from palmoplantar psoriasis, controlled 
clinical trials are necessary.
Alefacept in nail psoriasis
Involvement of the nails is common in patients with psoriasis. 
Psoriatic nail disease can be refractory to treatment because 
therapeutic options are limited. Recently an open-labeled 
study aimed to determine the efﬁ  cacy and safety of alefacept 
in patients suffering from nail psoriasis (Parrish et al 2006). 
Fifteen patients with moderate to severe nail psoriasis mea-
sured according to the Nail Psoriasis Severity Index (NPSI) 
were treated with alefacept administered i.m. 33% of the 
treated patients reached a reduction of NPSI of at least 50% 
whereas the median decrease was 38%. These data show that 
alefacept might represent an additional therapeutic option 
for nail psoriasis but further studies are necessary in order 
to conﬁ  rm the positive results of this study.
Effect of alefacept on the quality 
of life (QOL) of psoriasis patients
Psoriasis can seriously affect patient’s QOL. The impact of 
the chronic disease on social relations, psychological status, 
and daily activities was evaluated recently by the National 
Psoriasis Foundation. In a large inquiry (more than 17,000 
respondents) a profound inﬂ  uence of psoriasis on patients’ Therapeutics and Clinical Risk Management 2007:3(3) 419
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QOL could be shown, including adverse psychosocial effects, 
impaired daily activities, anxiety, and depression (Krueger 
et al 2001). Many patients reported feeling restrained in 
their lifestyle. Approximately 50% of the patients were not 
satisﬁ  ed with their therapies and 75% of the patients with 
severe disease were frustrated with the lack of efﬁ  cacy on 
their current treatment.
In phase II and III studies with alefacept, QOL was 
measured with the dermatology-specific QOL index, a 
practical questionnaire technique (DLQI) (Finlay and Khan 
1994). Signiﬁ  cant improvements of QOL in patients treated 
with alefacept compared with placebo treatment could be 
observed. In a phase II study accomplished in 2003 an 
association between the clinical effect of alefacept on 
psoriasis and improvement in patients’ QOL could be shown. 
Patients treated with alefacept had significantly greater 
improvement of QOL compared with patients receiving 
placebo (Ellis et al 2003; van de Kerkhof et al 2005). In a 
phase III study alefacept also improved QOL in patients with 
chronic plaque psoriasis. This beneﬁ  t was maintained for at 
least 12 weeks after treatment. A second course of alefacept 
was demonstrated to lead to a further increase of the QOL 
in these patients (Finlay et al 2003; Feldman et al 2004; van 
de Kerkhof et al 2005).
Conclusion
Clinical data from different studies conﬁ  rm the efﬁ  cacy of 
alefacept, which improves psoriasis with durable remission 
without any signiﬁ  cant impact on the immune function of 
T cells. The data currently available show a favorable safety 
proﬁ  le over short-term treatment (Goffe et al 2005) with few 
apparent side-effects and no clear link to serious infections, 
malignancies, or other serious adverse events (Scheinfeld 
2005a). Until now no correlation between the reduced CD4+ 
and CD8+ T cell counts under alefacept treatment and an 
increased risk for the development of serious infections 
or malignancies has been observed. Further, alefacept has 
been shown to be well-tolerated in a broad spectrum of pa-
tients’ including old, diabetic, and obese patients (Gottlieb 
et al 2005). Unfortunately the number of non-responders is 
relatively high and the long-term remission has been shown 
only in patients achieving PASI 75, which means only one 
third of all treated patients. Clinical studies should further 
evaluate the possibility of coupling alefacept with topical 
or ultraviolet light therapy in order to enhance the patient’s 
clinical results. 
Even if most of the studies published on the treatment of 
chronic plaque psoriasis seem to provide promising data, it has 
to be remembered that the signiﬁ  cance of these studies might 
be limited by high drop-out rates which may bias analyses 
because patients not responding to treatment may selectively 
drop out of studies, skewing the results to good responses. 
Further, it is always possible that studies with lower response 
rates and less success might remain unpublished.
In summary alefacept represents a safe alternative 
therapeutic option for the treatment of adult people suf-
fering from moderate to severe chronic plaque psoriasis 
with contraindications or resistance to traditional systemic 
therapies. Potential limitations for the use of alefacept 
include high costs of treatment, insufﬁ  cient data available 
for long-term follow-up, a high number of non-responders, 
and the fact that it often takes several months of treatment 
to discover that the patient does not respond to alefacept 
because of missing valuable and early read-out parameters 
for responders and non-responders. Additionally it should 
be noted that the transient decrease of CD4+ T cells under 
therapy requires monitoring of lymphocytes counts as well 
as regular re-evaluation of potential signs of infections or 
malignancies during treatment with alefacept. 
Ongoing research should focus on the use of alefacept in 
combination with other treatment forms for speciﬁ  c recalcitrant 
cases, the expansion of safety assessment studies in patients of 
different risk groups, and the efﬁ  cacy of alefacept treatment in 
patients with other psoriasis-related disorders such as psoria-
sis arthritis or nail psoriasis (Korver et al 2006). Much effort 
should be put into identifying parameters to deﬁ  ne subgroups 
of patients with a high probability to respond or not respond to 
the treatment at the earliest possible time point during treatment 
or, if applicable, before the start of treatment. 
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